Caxton Associates LP Atara Biotherapeutics, Inc. Transaction History

Caxton Associates LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$1.5 - $3.04 $73,981 - $149,935	-49,321 Reduced 46.76%	56,151 $90,000
Q1 2023 May 15, 2023	SELL	$2.8 - $5.46 $263,799 - $514,408	-94,214 Reduced 47.18%	105,472 $305,000
Q4 2022 Feb 14, 2023	BUY	$2.85 - $5.18 $7,581 - $13,778	2,660 Added 1.35%	199,686 $654,000
Q3 2022 Nov 14, 2022	BUY	$2.85 - $8.73 $526,055 - $1.61 Million	184,581 Added 1483.17%	197,026 $745,000
Q2 2022 Aug 15, 2022	BUY	$4.69 - $9.84 $58,367 - $122,458	12,445 New	12,445 $97,000

85M

18.4K

51.3K

Ticker ATRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,362,304
Market Cap $802M
Description
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...

Get notified when there are updates to the investment portfolio of Caxton Associates LP, based on Form 13F filings with the SEC.

Stay updated on Caxton Associates LP with notifications on news.